Investor Relations

Stock Quote - Ticker Tape

 

SEC Filings

  o View CEL-SCI's SEC Filings  
       

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o Press Releases  
  JULY 30, 2014
NEW STORY France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial
  JULY 22, 2014
NEW STORY CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey
  JULY 17, 2014
NEW STORY CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka
  JULY 15, 2014
NEW STORY CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
  JULY 11, 2014
NEW STORY CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference
  JULY 8, 2014
NEW STORY CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI'S Phase III Head and Neck Cancer Trial into Austria
  JULY 1, 2014
NEW STORY CEL-SCI Reports 93% Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
  JUNE 3, 2014
CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
  JUNE 2, 2014
CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the United Kingdom
 

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com